menu

New and Emerging Therapies for Complex Epileptic Syndromes

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

New and Emerging Therapies for Complex Epileptic Syndromes

3 chapters
Play All
0.75 credits
45 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.75 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    This Expert Exchange webcast is designed to enhance clinicians’ awareness of emerging pharmacotherapies that demonstrate promise in optimizing seizure burden in patients with Lennox-Gastaut and Dravet syndromes.

  • Target Audience

    This activity has been designed to meet the educational needs of neurologists, epileptologists and other healthcare professionals who manage patients with Lennox-Gastaut and Dravet syndromes.

  • Educational Objectives

    Upon completion of this activity, participants will be better able to do the following:

    • Define terminology and prevalence of childhood-onset syndromes, particularly developmental and epileptic encephalopathies (DEE).
    • Identify current treatment strategies for managing patients with LGS and DS, and challenges associated with them.
    • Summarize the efficacy and safety profiles of emerging pharmacotherapies for the management of patients with LGS and DS.
  • Financial Support

    This activity is supported by an independent educational grant from Takeda Pharmaceutical Co.

  • Provider(s)/Educational Partner(s)


    Jointly provided by Medical Education Resources and Novus Medical Education.

  • Accreditation and Credit Designation Statements

    Joint Accreditation Statement

     In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Novus Medical Education. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation for Physicians
    MER designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclosure of Conflicts of Interest

    MER requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is t producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity. 

     

    MER has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity. The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

    Dr. Wirrell discloses the following relationships:
    Advisor/Consultant: Amicus, Acadia, Encoded Therapeutics, Neurocrine

    Dr. Sullivan discloses the following relationships:
    Advisor/Consultant: Epygenix Therapeutics, Bright Minds, Longboard, Praxis, CAMP4
    Research Support: Zogenix, Stoke Therapeutics, Bio-Pharm Solutions (ended), Encoded Therapeutics, Xenon Pharmaceuticals, Neurocrine Biosciences, Takeda
    Stock/Stock Options: Epygenix Therapeutics

    The directors, planners, managers and reviewers of this activity reported no relevant financial relationships with an ineligible company during the past 24 months.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Method of Participation

    There are no fees for participating and receiving CME credit for this activity. To claim credit, participants must complete the following:

    1. Read the educational objectives, accreditation information and faculty disclosures at the beginning of this activity.
    2. Complete the pre-test.
    3. View the webcast.
    4. Complete the post-test and evaluation.
    5. Physicians who receive a grade of 75% or better on the post-test and complete the evaluation will receive a CME certificate.
    6. All other participants who receive a grade of 80% or better on the post-test and complete the evaluation will receive a Certificate of Participation.
  • CME Provider

    For information about the certification of this activity, please contact MER at info@cmepartner.org or 800.421.3756.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    This Expert Exchange webcast is designed to enhance clinicians’ awareness of emerging pharmacotherapies that demonstrate promise in optimizing seizure burden in patients with Lennox-Gastaut and Dravet syndromes.

  • Target Audience

    This activity has been designed to meet the educational needs of neurologists, epileptologists and other healthcare professionals who manage patients with Lennox-Gastaut and Dravet syndromes.

  • Educational Objectives

    Upon completion of this activity, participants will be better able to do the following:

    • Define terminology and prevalence of childhood-onset syndromes, particularly developmental and epileptic encephalopathies (DEE).
    • Identify current treatment strategies for managing patients with LGS and DS, and challenges associated with them.
    • Summarize the efficacy and safety profiles of emerging pharmacotherapies for the management of patients with LGS and DS.
  • Financial Support

    This activity is supported by an independent educational grant from Takeda Pharmaceutical Co.

  • Provider(s)/Educational Partner(s)


    Jointly provided by Medical Education Resources and Novus Medical Education.

  • Accreditation and Credit Designation Statements

    Joint Accreditation Statement

     In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Novus Medical Education. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation for Physicians
    MER designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclosure of Conflicts of Interest

    MER requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is t producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity. 

     

    MER has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity. The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

    Dr. Wirrell discloses the following relationships:
    Advisor/Consultant: Amicus, Acadia, Encoded Therapeutics, Neurocrine

    Dr. Sullivan discloses the following relationships:
    Advisor/Consultant: Epygenix Therapeutics, Bright Minds, Longboard, Praxis, CAMP4
    Research Support: Zogenix, Stoke Therapeutics, Bio-Pharm Solutions (ended), Encoded Therapeutics, Xenon Pharmaceuticals, Neurocrine Biosciences, Takeda
    Stock/Stock Options: Epygenix Therapeutics

    The directors, planners, managers and reviewers of this activity reported no relevant financial relationships with an ineligible company during the past 24 months.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Method of Participation

    There are no fees for participating and receiving CME credit for this activity. To claim credit, participants must complete the following:

    1. Read the educational objectives, accreditation information and faculty disclosures at the beginning of this activity.
    2. Complete the pre-test.
    3. View the webcast.
    4. Complete the post-test and evaluation.
    5. Physicians who receive a grade of 75% or better on the post-test and complete the evaluation will receive a CME certificate.
    6. All other participants who receive a grade of 80% or better on the post-test and complete the evaluation will receive a Certificate of Participation.
  • CME Provider

    For information about the certification of this activity, please contact MER at info@cmepartner.org or 800.421.3756.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule23 Feb 2024